Gunilla Osswald
About
Gunilla Osswald is CEO of BioArctic AB, a Swedish biotechnology company focused on neurodegenerative diseases including Alzheimer's and Parkinson's disease. BioArctic co-developed lecanemab, marketed as Leqembi, a groundbreaking amyloid-targeting antibody therapy approved for early Alzheimer's disease in partnership with Eisai. She is one of the most prominent biotech executives in the Nordic region, leading a company that achieved a major therapeutic milestone.
Know Gunilla Osswald?
We list a record's team, investors, portfolio and events once we can verify them. Send us what you know and we'll check it.
Suggest an edit